

PAAM Training Webinar Series: “Mistletoe Use in Cancer Therapy” with Peter Hinderberger MD

This two-part webinar reviews the basics uses, clinical indications, and contraindications for the use of mistletoe as an adjuvant cancer treatment. Dr. Hinderberger has many years of experience in the use mistletoe. The first session will present an overview of mistletoe therapy; the second will look at more specific clinical questions or situations.

Target group:

professional licensed prescribers, participation is therefore limited to MD's, DO's, NP's, PA's and ND graduates of accredited four year programs

Course Outline:

Session I: Thursday, January 28th, 2016 (Peter Hinderberger MD)

1. History of mistletoe as a medicinal plant
2. Its use within anthroposophic medicine
3. Characteristics of the plant, including growth characteristics and seasonal patterns
4. Phenomenological overlap between tumor growth and mistletoe
5. Modes of action, bioactive ingredients in mistletoe
6. In vitro studies
7. Clinical indications
8. Clinical studies
9. Contraindications, side effects
10. Protocol for adjunct therapy in cancer

Session II: Thursday, February 11th, 2016 (Peter Hinderberger MD)

1. Further discussion of clinical studies
2. Sample cases

References:

1. Anand P, Sundaram C, Jhurani S, Kunnumakkara AB: Curcumin and cancer: an “old-age” disease with an “age-old” solution. *Cancer letters*, 2008 - Elsevier
2. Augustin M, Bock PR, Hanisch J, Karasmann M, Schneider B: Efficacy and safety of the long-term treatment with standardized European mistletoe extract Iscador compared with parallel control group in high-risk non-metastatic malignant melanoma. Multicentric, comparative, retrospective, pharmaco-epidemiological cohort study in Germany and Switzerland. *In Vorbereitung Korrespondenzadresse* 2004.
3. Bantel H, Engels IH, Voelter W, Schulze-Osthoff K, Wesselborg S: Mistletoe lectin activates caspase-8/FLICE independently of death receptor signaling and enhances anticancer drug-induced apoptosis. *Cancer Research* 1999, 59:2083-2090.
4. Bar-Sela G, Wollner M, Hammer L, Agbarya A, Dudnik E, Haim N: Mistletoe as complementary treatment in patients with advanced non-small-cell lung cancer treated with carboplatin-based combinations: A randomised phase II study. *European Journal of Cancer* 2013, 49(5):1058-1064.
5. Bock PR, Friedel WE, Hanisch J, Karasmann M, Schneider B: Efficacy and safety of long-term complementary treatment with standardized European mistletoe extract (*Viscum album* L.) in addition to the conventional adjuvant oncologic therapy in patients with primary non-metastasized mammary carcinoma. Results of a multi-

- center, comparative, epidemiological cohort study in Germany and Switzerland. *Arzneimittel-Forschung/Drug Research* 2004, 54 (8):456-466.
6. Burger AM, Mengs U, Schler JB, Fiebig HH: Antiproliferative activity of an aqueous mistletoe extract in human tumor cell lines and xenografts in vitro. *Arzneimittel-Forschung/Drug Research* 2001, 51(9):748-757.
 7. Burkhart J, Walchli C, Heusser P, Weissenstein U, Baumgartner S, Andres AC: In vitro investigation into the potential of a mistletoe extract to alleviate adverse effects of cyclophosphamide. *Altern Ther Health Med* 2010, 16(3):40-48.
 8. Büssing A, Azhari T, Ostendorp K, Lehnert A, Schweizer K: Viscum album L. extracts reduce sister chromatid exchanges in cultured peripheral blood mononuclear cells. *European Journal of Cancer* 1994, 30A(12):1836-1841.
 9. Büssing A, Jungmann H, Suzart K, Schweizer K: Suppression of sister chromatid exchange-inducing DNA lesions in cultured peripheral blood mononuclear cells by Viscum album L. *Journal of Experimental and Clinical Cancer Research* 1996, 15:107-114.
 10. Büssing A, Regnery A, Pfler U, Schweizer K: The antimutagenic properties of Viscum album L.: What's up in mistletoes? *Cancer Research Clinical Oncology* 1995, 121(Suppl.2):A58-A58.
 11. Büssing A, Lehnert A, Schink M, Mertens R, Schweizer K: Effect of Viscum album L. on rapidly proliferating amniotic fluid cells. *Arzneimittel-Forschung/Drug Research* 1995, 45(1)(1):81-83.
 12. Büssing A, Jurin M, Zarkovic N, Azhari T, Schweizer K: DNA-stabilisierende Wirkungen von Viscum album L. - Sind Mistelextrakte als Adjuvans w„hrend der konventionellen Chemotherapie indiziert? *Forschende Komplement„rmedizin/ Research in Complementary Medicine* 1996(3):244-248.
 13. Büssing A: Induction of apoptosis by the mistletoe lectins: a review on the mechanisms of cytotoxicity mediated by Viscum album L. *Apoptosis* 1996(1):25-32.
 14. Büssing A: Mistletoe. The Genus Viscum Amsterdam: Hardwood Academic Publishers; 2000.
 15. Cameron E, Campbell A: The orthomolecular treatment of cancer. II. Clinical trial of high-dose ascorbic acid supplements in advanced human cancer. *Chem Biol Interact* 9 (4): 285-315, 1974. [PUBMED Abstract]
 16. Cameron E, Campbell A, Jack T: The orthomolecular treatment of cancer. III. Reticulum cell sarcoma: double complete regression induced by high-dose ascorbic acid therapy. *Chem Biol Interact* 11 (5): 387-93, 1975. [PUBMED Abstract]
 17. Cameron E, Pauling L: Supplemental ascorbate in the supportive treatment of cancer: Prolongation of survival times in terminal human cancer. *Proc Natl Acad Sci U S A* 73 (10): 3685-9, 1976. [PUBMED Abstract]
 18. Cameron E, Pauling L: Supplemental ascorbate in the supportive treatment of cancer: reevaluation of prolongation of survival times in terminal human cancer. *Proc Natl Acad Sci U S A* 75 (9): 4538-42, 1978. [PUBMED Abstract]
 19. Carlson LE, Ursuliak Z, Goodey E, Angen M: The effects of a mindfulness meditation-based stress reduction program on mood and symptoms of stress in cancer outpatients: 6-month follow-up ... - ... care in Cancer, 2001 - Springer
 20. Doehmer J, Eisenbraun J: Assessment of extracts from mistletoe (Viscum album) for herb-drug interaction by inhibition and induction of cytochrome P450 activities. *Phytotherapy Research* 2012, 26(1):11-17.
 21. Douwes FR, Kalden M, Frank G, Holzhauer P: [Treatment of the advanced colo-rectal carcinoma] Behandlung des fortgeschrittenen kolorektalen Karzinoms. *Deutsche Zeitschrift fr Onkologie* 1988, 20(3):63-67.

22. Douwes FR, Wolfrum DI, Migeod F: [Results of a prospective randomized trial: Chemotherapy versus Chemotherapy plus biologic response modifier of the metastatic colo-rectal carcinoma] Ergebnisse einer prospektiv randomisierten Studie: Chemotherapie versus Chemotherapie plus "Biological Response Modifier" bei metastasierendem kolorektalen Karzinom. *Krebsgeschehen* 1986, 18(6):155-163.
23. Engdal S, Nilsen OG: In vitro inhibition of CYP3A4 by herbal remedies frequently used by cancer patients. *Phytother Res* 2009, 23(7):906-912.
24. Fritz P, Mrdter TE, Siegle I, Aulitzky W, Voelter W: Therapie mit Mistelextrakten in der Onkologie: eine Kontroverse ohne Ende? *Urologe* 2001, 41(5B):466-471.
25. Grah C, Matthes B, Happel H, Lemmens HP: Randomisierte, offene Phase-II-Studie zur Untersuchung von *Viscum album*-Extrakt in der palliativen, additiven Behandlung des fortgeschrittenen nichtkleinzelligen Bronchialkarzinoms (NSCLC). In: *Die Mistel in der Tumorthherapie 3 Aktueller Stand der Forschung und klinische Anwendung*. edn. Edited by Scheer R, Alban S, Becker H, Blaschek W, Kreis W, Matthes H, Schilcher H, Stange R. Essen: KVC Verlag; 2013: 389-401.
26. Grah C: Misteltherapie bei nichtkleinzelligem Bronchialkarzinom. Randomisierte, offene Phase-II-Studie zur Untersuchung der Verträglichkeit und Wirksamkeit von *Viscum album*-Extrakt in der palliativen, additiven Behandlung des fortgeschrittenen nichtkleinzelligen Bronchialkarzinoms. GKH Havelh"he, Akademisches Lehrkrankenhaus der medizinischen Fakultät der Charit,, Universität,medizin Berlin; 2010.
27. Gutsch J, Berger H, Scholz G, Denck H: Prospektive Studie beim radikal operierten Mammakarzinom mit Polychemotherapie, Helixor und unbehandelter Kontrolle. *Deutsche Zeitschrift fr Onkologie* 1988(4):94-100.
28. Hamre HJ1, Witt CM, Glockmann A, Ziegler R, Willich SN, Kiene H: Anthroposophic art therapy in chronic disease: a four-year prospective cohort study. *HExplore (NY)*. 2007 Jul-Aug;3(4):365-71. 33.
29. Harald J Hamre1*, Claudia M Witt2, Anja Glockmann1, Renatus Ziegler3, Stefan N Willich2 and Helmut Kiene1 Eurythmy therapy in chronic disease: a four-year prospective cohort study
30. Jurin M, Zarkovic N, Borovic S, Kissel D: Immunomodulation by the *Viscum album* L. preparation Isorel and its antitumorous effects. In: *Grundlagen der Misteltherapie Aktueller Stand der Forschung und klinische Anwendung*. edn. Edited by Scheer R, Becker H, Berg PA. Stuttgart: Hippokrates Verlag GmbH; 1996: 315-324.
31. Jurin M, Zarkovic N, Hrzenjak M, Ilic Z: Antitumorous and immunomodulatory effects of the *Viscum album* L. preparation Isorel. *Oncology* 1993, 50:393-398.
32. 56. Kawamori T, Lubet R, Steele VE, Kelloff GJ, Kaskey RB: Chemopreventive effect of curcumin, a naturally occurring anti-inflammatory agent, during the promotion/progression stages of colon cancer. *Cancer research*, 1999 - AACR
33. Kienle GS, Kiene H: Influence of *Viscum Album* L (European Mistletoe) Extracts on Quality of Life in Cancer Patients: A Systematic Review of Controlled Clinical Studies. *Integr Cancer Ther* 2010, 9(2):142-157.
34. Kienle GS, Kiene H: Die Mistel in der Onkologie - Fakten und konzeptionelle Grundlagen. Stuttgart, New York: Schattauer Verlag; 2003.
35. Kovacs E, Kuehn JJ, Werner M, Hoffmann J: Effect of Iscador on DNA-repair after radiation or cyclophosphamide. Correlation with IFN- γ production. *Onkologie* 1995, 18(S2):651.

36. Kovacs E, Hajto T, Hostanska K: Improvement of DNA repair in lymphocytes of breast cancer patients treated with *Viscum album* extract (Iscador). *European Journal of Cancer* 1991, 27(12):1672-1676.
37. Lange O, Scholz G, Gutsch J: [Influence of aggressive chemotherapy and Helixor on subjective and objective toxicity] Modulation der subjektiven und objektiven Toxizität einer aggressiven Chemotherapie mit Helixor. Unpublished Report In.; 1985.
38. Mansky PJ, Wallerstedt DB, Sannes TS, Stagl J, Johnson LL, Blackman MR, Grem JL, Swain SM, Monahan BP: NCCAM/NCI Phase 1 Study of Mistletoe Extract and Gemcitabine in Patients with Advanced Solid Tumors. *Evidence-Based Complementary and Alternative Medicine* 2013, 2013:964592.
39. Marx WM, Teleni L, McCarthy AL, et al. Ginger (*Zingiber officinale*) and chemotherapy-induced nausea and vomiting: a systematic literature review. *Nutr Rev.* 2013;71:245-54.
40. Matthes H, Friedel WE, Bock PR, Zanker KS: Molecular mistletoe therapy: friend or foe in established anti-tumor protocols? A multicenter, controlled, retrospective pharmaco-epidemiological study in pancreas cancer. *Curr Mol Med* 2010, 10(4):430-439.
41. Miller S, Stagl J, Wallerstedt DB, Ryan M, Mansky PJ: Botanicals used in complementary and alternative medicine treatment of cancer: clinical science and future perspectives.
42. Puetz TW, Morley CA, Herring MP: Effects of creative arts therapies on psychological symptoms and quality of life in patients with cancer. *JAMA Intern Med.* 2013 Jun 10;173(11):960-9. doi: 10.1001/jamainternmed.2013.836.
43. Rose, A, et al: Nonmuscle invasive bladder cancer, Phase I/II study on intravesical mistletoe therapy. *The Journal of Urology* 2015, 194: 939-943
44. Rostock M, Huber R, Greiner T, Fritz P, Scheer R, Schueler J, Fiebig HH: Anticancer activity of a lectin-rich mistletoe extract injected intratumorally into human pancreatic cancer xenografts. *Anticancer Research* 2005, 25(3B):1969-1975.
45. Ryan JL, Heckler CE, Roscoe JA, et al. Ginger (*Zingiber officinale*) reduces acute chemotherapy-induced nausea: a URCC CCOP study of 576 patients. *Support Care Cancer.* 2012;20:1479-89.
46. Seifert G, Driever PH, Pretzer K, Edelhäuser F: Effects of complementary eurythmy therapy on heart rate variability , ... - ... therapies in medicine, 2009 – Elsevier
47. Siegle I, Fritz P, McClellan M, Gutzeit S, Murdter TE: Combined cytotoxic action of *Viscum album* agglutinin-1 and anticancer agents against human A549 lung cancer cells. *Anticancer Research* 2001, 21(4A):2687-2691.
48. Strüh CM, et al: Treatment with triterpenoid-enriched mistletoe extracts reduces tumor size and angiogenesis in B16.F10 melanomas.. (2013). *PLoS ONE* 8(4): e62168. doi:10.1371/journal.pone.0062168
49. Thoma MV, La Marca R, Brönnimann R, Finkel L, Ehlert U, and Nater UM: The Effect of Music on the Human Stress Response. Robert L. Newton, Editor
50. Toneatto T, Nguyen L: Does mindfulness meditation improve anxiety and mood symptoms? A review of the controlled research - *Canadian Journal of Psychiatry*, 2007 - search.proquest.com
51. Tröger W, Zdravle Z, Stankovi N, Matijassjevi M: Five-Year Follow-Up of patients with early stage Breast cancer After a Randomized study comparing Additional Treatment with *Viscum Album* (L.) extract to chemotherapy Alone. *Breast Cancer: Basic and Clinical Research* 2012, 6:173.

52. Tsai HH, Lin HW, Simon Pickard A: Evaluation of documented drug interactions and contraindications associated with herbs and dietary supplements: a systematic literature review ... - ... journal of clinical ..., 2012 - Wiley Online Library
53. Valentiner U, Pfler U, Baum C, Schumacher U: The cytotoxic effect of mistletoe lectins I, II and III on sensitive and multidrug resistant human colon cancer cell lines in vitro. *Toxicology* 2002, 171(2-3):187-199.
54. Weissenstein U, Kunz M, Urech K, Baumgartner S: Interaction of standardized mistletoe (*Viscum album*) extracts with chemotherapeutic drugs regarding cytostatic and cytotoxic effects in vitro. *BMC Complement Altern Med* 2014, 14:6.
55. Williams GC, Frankel RM, Campbell TL: Research on relationship-centered care and healthcare outcomes from the Rochester Biopsychosocial Program: a self-determination theory integration.
56. Wilson PM, Blanchard CM, Nehl E, Baker F: Predicting physical activity and outcome expectations in cancer survivors: an application of Self-Determination Theory - *Psycho-Oncology*, 2006 - Wiley Online Library
57. Wu SD, Lo PC: Inward-attention meditation increases parasympathetic activity: a study based on heart rate variability - *Biomedical Research*, 2008 - jlc.jst.go.jp